We also investigated the prognostic impact of the immune-related markers across the 3 breast cancer subtypes: hormone receptor negative/HER2− (TN), hormone receptor positive/HER2− (HR+), and hormone receptor positive or hormone receptor negative/ HER2+ (HER2+). The gene discussed is ERBB2; the disease is breast carcinoma.